CAR-T Vector Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In the realm of cutting-edge immunotherapy, CAR-T cell therapy has emerged as a revolutionary approach in the fight against cancer and other debilitating diseases. Creative Biolabs, with its rich history and expertise in the field of biotechnology, has been at the forefront of developing CAR-T therapies for over two decades.

CAR-T vectors play an indispensable role in the CAR-T therapy process. These vectors serve as vehicles for introducing the CAR construct into the patient's T-cells. Once inside the T-cells, the CAR construct enables these immune cells to specifically recognize and target cancer cells.

Creative Biolabs provides an extensive array of CAR vectors, encompassing various generations and vector types, catering to diverse requirements and preferences.

CAR Vector Types

Viral Vectors

Viral vectors, such as lentiviral vectors and retroviral vectors, are the most commonly employed vehicles for CAR-T engineering. They offer several advantages, including efficient transduction and stable integration of the CAR construct into the T cell genome. Lentiviral vectors, for instance, have a broad tropism and can infect both dividing and non-dividing cells, making them ideal for CAR-T applications.

Non-viral Vectors

Non-viral vectors, on the other hand, encompass various methods like electroporation and transposon-based systems. While they do not rely on viral components, they can be more challenging to optimize for consistent CAR expression and may lead to transient CAR expression.

We offer customized design services for CAR vectors across various generations:

Fig.1 Generations of CAR-T-cell construct designs.¹

CAR Vector Design

The design of CARs is a critical aspect of CAR-T therapy, and it heavily influences the vectors used. CARs consist of three main components: the extracellular antigen-binding domain, a hinge and transmembrane domain, and the intracellular signaling domain. Each component is meticulously engineered to enhance CAR-T cell specificity, persistence, and functionality.

Extracellular Antigen-Binding Domain: This component determines CAR-T cell specificity by recognizing the target antigen. Careful selection of this domain ensures that CAR-T cells exclusively target cancer cells while sparing healthy tissues.
Hinge and Transmembrane Domain: These elements play a crucial role in CAR-T cell activation and signaling. Optimizing their design can enhance CAR-T cell persistence and efficacy.
Intracellular Signaling Domain: The intracellular domain is responsible for transmitting activation signals to the T cell. The choice of signaling domains, such as CD28 or 4-1BB, can impact CAR-T cell expansion and cytokine production

Customization for Specific Needs

As a leading player in the CAR-T therapy industry, Creative Biolabs offers a range of customized services tailored to meet the unique needs of our clients. Our expertise in CAR-T vector design and development extends to:

Vector Selection: We help you choose the most suitable vector platform based on your specific requirements and target cells.
CAR Design and Optimization: Our team of experts specializes in designing CARs with enhanced specificity and functionality, ensuring optimal therapeutic outcomes.
Vector Production: We employ cutting-edge techniques to produce high-quality viral and non-viral vectors for CAR-T cell engineering.
Quality Control: Rigorous quality control measures are implemented to guarantee vector safety and efficacy.

We have developed a proprietary online system for customizing CAR and CAR cell products, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.

Reference

Rallis, Kathrine S., et al. "T-cell-based immunotherapies for haematological cancers, Part B: A SWOT analysis of adoptive cell therapies." Anticancer Research 41.3 (2021): 1143-1156.